PELL Bio-Med Technology Co Ltd AI Stock Analysis
PELL Bio-Med Technology Co Ltd (6949) AI Stock Analysis
PELL Bio-Med Technology Co Ltd
(TWSE:6949)
The score is driven primarily by weak financial performance: widening operating and net losses, escalating cash burn of roughly NT$500m in free cash outflow, and a complete dependence on external financing, only partly offset by a conservative, low-debt balance sheet and encouraging gross-margin improvement. Technicals reinforce the caution, with the price below all key moving averages and a negative MACD. Valuation provides no cushion given negative earnings and no dividend. Investors should treat this as a speculative, early-stage biotech where the outcome hinges on scaling commercial revenue before further dilutive fundraising is needed.
PELL Bio-Med Technology Co Ltd (6949) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 54.80B
- Dividend Yield
- ―
- Average Volume (3M)
- 6.81M
- Price to Earnings (P/E)
- -138.2
- Beta (1Y)
- 0.98
- Revenue Growth
- 7.81%
- EPS Growth
- ―
- Country
- TW
- Employees
- 94
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
PELL Bio-Med Technology Co Ltd Business Overview & Revenue Model
Company Description
Pell Bio-Med Technology Co., Ltd., established in 2017 and headquartered in Taipei, Taiwan, operates as a biomedical firm specializing in advanced cell culture technologies and methods for therapeutic applications. The company's commercial portfolio...
PELL Bio-Med Technology Co Ltd Financial Statement Overview
Summary
Financials reflect a high-risk, development-stage biotech. Revenue is growing fast in percentage terms (roughly NT$31.4m, +60%) and gross loss narrowed sharply from NT$42.3m to NT$4.4m, but operating and net losses continue to widen (net loss ~NT$424m) and cash burn is severe, with operating cash flow of about -NT$281m and free cash flow near -NT$509m. The balance sheet is the offsetting strength: equity of ~NT$1.42bn, total debt down to ~NT$237m and debt-to-equity of just 0.17. However, that equity was built through capital raises rather than profits, implying dilution risk and a finite runway against ~NT$500m of annual cash outflow.
Income Statement
21NegativeBalance Sheet
57NeutralCash Flow
13Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 28.93M | 31.42M | 19.63M | 18.03M | 17.16M | 13.98M |
| Gross Profit | -14.29M | -4.39M | -12.33M | -26.14M | -42.30M | -34.53M |
| EBITDA | -443.14M | -420.23M | -346.09M | -353.18M | -198.87M | -157.29M |
| Net Income | -451.13M | -423.94M | -389.42M | -398.76M | -230.13M | -188.96M |
Balance Sheet | ||||||
| Total Assets | 3.16B | 2.11B | 1.74B | 1.42B | 1.04B | 393.89M |
| Cash, Cash Equivalents and Short-Term Investments | 2.27B | 1.31B | 1.14B | 1.11B | 708.40M | 115.78M |
| Total Debt | 231.52M | 237.40M | 364.84M | 172.56M | 202.78M | 141.06M |
| Total Liabilities | 333.59M | 418.27M | 458.62M | 236.76M | 229.79M | 169.02M |
| Stockholders Equity | 2.57B | 1.42B | 1.18B | 1.17B | 800.94M | 224.86M |
Cash Flow | ||||||
| Free Cash Flow | -628.07M | -508.89M | -524.10M | -196.47M | -164.17M | -122.99M |
| Operating Cash Flow | -399.90M | -281.29M | -260.12M | -179.99M | -155.68M | -108.51M |
| Investing Cash Flow | -76.76M | -497.14M | -95.51M | -419.63M | -535.97M | 83.90M |
| Financing Cash Flow | 1.72B | 657.76M | 615.32M | 594.89M | 748.27M | -4.56M |
PELL Bio-Med Technology Co Ltd Peers Comparison
Overall Rating
TW:649176Outperform
TW:647260Neutral
TW:179557Neutral- TW:694933Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TW:6491 | 76Outperform | TWD 31.20B | 15.39 | ― | 2.55% | 18.45% | 24.17% |
| TW:6472 | 60Neutral | TWD 50.12B | 32.71 | ― | 2.48% | -5.57% | -62.77% |
| TW:1795 | 57Neutral | TWD 44.28B | 10.79 | ― | 1.64% | 48.98% | -21.95% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| TW:6949 | 33Underperform | TWD 54.47B | -138.20 | ― | ― | 7.81% | ― |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:6949 | PELL Bio-Med Technology Co Ltd | 44.75 | 25.91 | 137.55% | |
| TW:1795 | Lotus Pharmaceutical Co., Ltd. | 156.00 | -123.55 | -44.20% | |
| TW:6472 | Bora Pharmaceuticals Co Ltd | 403.00 | -209.62 | -34.22% | |
| TW:6491 | Pegavision Corp. | 392.50 | 66.34 | 20.34% | |
| TW:7799 | Heron Neutron Medical Corp. | 432.00 | -178.00 | -29.18% | |
| TW:7924 | TLC BioSciences Corp | 402.50 | 192.00 | 91.21% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026